ENODL1 Antibody

What is ENO1 and why is it a significant research target?

ENO1 (α-enolase) is a multifunctional protein encoded by the ENO1 gene in humans. It is structurally a 47.2 kilodalton protein that may also be known under several other names including plasminogen binding protein, ENO1L1, HEL-S-17, MPB1, NNE, and c-myc promoter-binding protein-1. ENO1 has emerged as a significant research target due to its correlation with reduced survival and poor prognosis in multiple cancer types, including lung cancer. Its involvement in critical cellular processes and disease mechanisms makes it valuable for both basic research and potential therapeutic targeting .

What types of ENO1 antibodies are available for research applications?

Research-grade ENO1 antibodies are available in multiple formats including polyclonal and monoclonal variants with various reactivity profiles. According to current antibody databases, there are over 700 ENO1 antibodies available across different suppliers, offering options for detecting human, mouse, rat, and other species' ENO1 proteins. These antibodies come in unconjugated forms or with specific conjugates depending on the intended application. Most commonly, researchers can access antibodies validated for Western blotting, ELISA, immunohistochemistry (IHC), and immunofluorescence (IF) applications .

What are the standard experimental applications for ENO1 antibodies?

ENO1 antibodies are widely employed across multiple experimental applications including:

• Western blotting for protein expression analysis

• Immunohistochemistry for tissue localization studies (both IHC-p for paraffin-embedded samples)

• Immunofluorescence for subcellular localization

• ELISA for quantitative detection

• Immunoprecipitation for protein-protein interaction studies

The selection of application should be guided by the specific antibody validation data provided by manufacturers, as not all antibodies perform equally across different techniques .

How should researchers evaluate specificity when selecting an ENO1 antibody?

When evaluating ENO1 antibody specificity, researchers should consider multiple validation parameters:

• Cross-reactivity testing: Verify the antibody has been tested against related proteins, particularly other enolase isoforms (ENO2, ENO3).

• Knockout/knockdown validation: Prioritize antibodies validated using ENO1 knockout or knockdown controls to confirm signal specificity.

• Epitope information: Understanding the exact epitope recognized can help predict potential cross-reactivity issues.

• Multiple detection methods: Confirm the antibody has been validated across different experimental techniques relevant to your research.

• Literature citations: Review publications that have successfully used the antibody in similar experimental contexts.

The gold standard approach combines both positive controls (where ENO1 is known to be expressed) and negative controls (ENO1-null samples) to definitively establish specificity .

What dilution ranges are typically effective for ENO1 antibodies in different applications?

Optimal dilution ranges for ENO1 antibodies vary by application:

• Western blotting: Typically 1:500-1:2,000 dilution

• Immunohistochemistry: Generally 1:50-1:200 dilution

• ELISA: Often requires higher concentration, approximately 1:100-1:500

• Immunofluorescence: Usually 1:100-1:500

These ranges serve as starting points that should be optimized for each specific antibody and experimental system. Performing a dilution series during initial validation is recommended to determine the optimal signal-to-noise ratio for your particular experimental conditions .

How should ENO1 antibodies be properly stored and handled to maintain activity?

Proper storage and handling of ENO1 antibodies is critical for maintaining their specificity and sensitivity:

• Long-term storage: Store at -20°C for up to one year in manufacturer-recommended buffer conditions.

• Short-term storage: For frequent use within one month, store at 4°C.

• Avoid freeze-thaw cycles: Repeated freezing and thawing can degrade antibody quality. Aliquot upon first thaw if multiple uses are planned.

• Buffer conditions: Most ENO1 antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.2.

• Working solutions: Diluted antibody solutions should be prepared fresh and used within 24 hours for optimal performance.

Following these guidelines ensures maximal antibody performance and reproducibility across experiments .

How can ENO1 antibodies be utilized in cancer research beyond detection?

ENO1 antibodies have demonstrated significant utility in cancer research beyond simple detection:

• Functional blocking: Certain anti-ENO1 monoclonal antibodies can inhibit cancer cell invasion, proliferation, and clone formation, particularly in cervical cancer models, suggesting therapeutic potential.

• Mechanistic studies: ENO1 antibodies have been used to elucidate interactions between ENO1 and other proteins like hepatocyte growth factor receptor (HGFR), revealing its role in activating signaling pathways that promote cancer metastasis.

• Therapeutic development: Chimeric anti-ENO1 monoclonal antibodies (such as chENO1-22) have been developed that can decrease cancer cell proliferation and invasion by inhibiting ENO1-mediated GSK3β inactivation.

• In vivo imaging: Labeled ENO1 antibodies can be used for tumor visualization in experimental models.

These applications highlight how ENO1 antibodies can advance from basic research tools to potential therapeutic agents .

What are the key considerations when developing therapeutic ENO1 antibodies?

Development of therapeutic ENO1 antibodies requires careful consideration of multiple factors:

• Binding specificity: Therapeutic antibodies must have exquisite specificity for ENO1 with minimal off-target binding.

• Antibody format: Determining the appropriate antibody format (full IgG vs. fragments) based on tissue penetration needs and half-life requirements.

• Fc effector functions: Deciding whether ADCC (antibody-dependent cellular cytotoxicity) or CDC (complement-dependent cytotoxicity) effector functions would benefit the therapeutic mechanism or should be silenced.

• Humanization: Mouse-derived antibodies must be humanized to reduce immunogenicity in human patients.

• Manufacturability: Early assessment of expression levels, aggregation propensity, and stability is critical for successful development.

• Mechanism of action: Understanding whether the antibody works by blocking protein-protein interactions, neutralizing activity, or triggering receptor internalization.

These considerations require thorough pre-clinical validation before advancing to therapeutic applications .

How do ENO1 antibodies contribute to understanding ENO1's role in cancer metastasis?

ENO1 antibodies have been instrumental in elucidating ENO1's role in cancer metastasis through multiple experimental approaches:

• Protein interaction studies: Immunoprecipitation with ENO1 antibodies has revealed that ENO1 interacts with hepatocyte growth factor receptor (HGFR) and activates HGFR and Wnt signaling via increased phosphorylation of HGFR and the Wnt coreceptor LRP5/6.

• Signaling pathway analysis: Western blotting with phospho-specific antibodies following ENO1 antibody treatment has shown that ENO1 decreases GSK3β activity via Src–PI3K–AKT signaling and inactivation of the β-catenin destruction complex.

• EMT marker regulation: ENO1 antibodies have demonstrated that ENO1 expression promotes upregulation of mesenchymal markers N-cadherin and vimentin and the epithelial-to-mesenchymal transition regulator SLUG, along with concurrent downregulation of E-cadherin.

• In vivo metastasis models: Therapeutic ENO1 antibodies have prevented lung tumor metastasis and prolonged survival in animal models, confirming ENO1's critical role in the metastatic process.

These findings collectively establish ENO1 as a key driver of cancer metastasis and identify it as a potential therapeutic target .

What are common causes of non-specific binding with ENO1 antibodies?

Non-specific binding with ENO1 antibodies can arise from several sources:

• Cross-reactivity with other enolase isoforms: ENO1 shares sequence homology with ENO2 (neuron-specific enolase) and ENO3 (muscle-specific enolase), potentially causing cross-reactivity.

• High antibody concentration: Excessive antibody concentrations frequently increase background signal.

• Insufficient blocking: Inadequate blocking can lead to non-specific antibody adherence to the experimental matrix.

• Sample preparation issues: Improper fixation or antigen retrieval can expose epitopes that promote non-specific binding.

• Secondary antibody cross-reactivity: The secondary detection antibody may recognize endogenous immunoglobulins in the sample.

To address these issues, researchers should perform careful antibody titration, include isotype controls, use knockout/knockdown samples as negative controls, and optimize blocking conditions for each specific application .

How can discrepancies in ENO1 detection across different techniques be resolved?

Discrepancies in ENO1 detection across different experimental techniques can be systematically addressed:

• Epitope accessibility: Different techniques (WB, IHC, IF) involve different sample preparation methods that may affect epitope accessibility. Try multiple antibodies targeting different epitopes.

• Denaturation sensitivity: Some antibodies recognize only denatured (Western blot) or native (immunoprecipitation) forms of ENO1. Verify antibody specifications for each application.

• Expression level thresholds: Techniques have different sensitivity thresholds; negative results in less sensitive methods may simply reflect expression below the detection limit.

• Post-translational modifications: Different cellular conditions may alter ENO1's post-translational modification state, affecting antibody recognition.

• Subcellular localization: ENO1 can localize to different cellular compartments (membrane, cytoplasm, nucleus) depending on cell type and conditions. Ensure proper subcellular fraction isolation.

When encountering discrepancies, validate findings using multiple antibodies and complementary techniques like mass spectrometry or mRNA expression analysis .

What control samples are essential for validating ENO1 antibody specificity in oncology research?

For rigorous validation of ENO1 antibody specificity in oncology research, several control samples are essential:

• Positive expression controls: Cell lines with known high ENO1 expression levels (e.g., metastatic lung cancer cell lines).

• Negative expression controls: ENO1 knockout or knockdown cell lines created using CRISPR/Cas9 or siRNA technology.

• Isotype controls: Matched isotype antibodies (same host species, isotype, and concentration) to control for non-specific binding.

• Peptide competition: Pre-incubation of the antibody with purified ENO1 peptide to demonstrate signal specificity.

• Normal vs. tumor tissue pairs: Paired normal and tumor tissue from the same patient to assess differential expression patterns.

• Cell lines with variable expression: Panel of cell lines with differing ENO1 expression levels to demonstrate correlation between antibody signal and known expression level.

This comprehensive control strategy ensures that observed signals truly represent ENO1 and not experimental artifacts .

How are ENO1 antibodies being used to study non-glycolytic functions of ENO1?

ENO1 antibodies are increasingly employed to investigate the diverse non-glycolytic functions of ENO1:

• Transcriptional regulation: Chromatin immunoprecipitation (ChIP) with ENO1 antibodies helps identify ENO1's role as a transcriptional regulator by binding to promoter regions of various genes.

• Membrane receptor functions: Surface labeling with ENO1 antibodies has revealed ENO1's role as a plasminogen receptor on cell surfaces, contributing to extracellular matrix degradation and cell migration.

• Stress response: Immunofluorescence with ENO1 antibodies shows ENO1 translocation during cellular stress responses such as hypoxia.

• Protein-protein interactions: Co-immunoprecipitation with ENO1 antibodies has identified novel interaction partners beyond the glycolytic pathway, including components of the cytoskeleton and signaling complexes.

• Post-translational modifications: Antibodies specific to modified forms of ENO1 help track how modifications like phosphorylation, acetylation, and SUMOylation affect ENO1's multifunctional roles.

These applications are expanding our understanding of ENO1 beyond its classic role in glycolysis to its functions in cancer progression, inflammation, and autoimmunity .

What are best practices for using ENO1 antibodies in multiplexed imaging applications?

Multiplexed imaging with ENO1 antibodies requires careful consideration of several technical aspects:

• Antibody species and isotype selection: Choose ENO1 antibodies from different host species or isotypes than other target antibodies to allow specific secondary detection.

• Fluorophore selection: Select fluorophores with minimal spectral overlap and consider brightness relative to expected ENO1 expression levels.

• Sequential staining: For same-species antibodies, consider sequential staining with complete elution between rounds or use directly conjugated primary antibodies.

• Cross-reactivity testing: Validate all antibodies in the panel individually before combining to ensure specificity.

• Blocking optimization: Develop a blocking strategy that works for all antibodies in the panel, potentially requiring more stringent conditions than single-antibody experiments.

• Automated analysis: Implement computational image analysis to quantify co-localization or expression patterns across multiple markers.

These practices ensure reliable detection of ENO1 alongside other markers in complex tissue environments or co-localization studies .

How can ENO1 antibodies be leveraged in developing cancer diagnostics and monitoring tools?

ENO1 antibodies offer significant potential for cancer diagnostics and monitoring tools:

• Tissue-based diagnostics: ENO1 antibodies in immunohistochemistry panels can help assess tumor aggressiveness and metastatic potential, particularly in lung and cervical cancers where ENO1 expression correlates with poor prognosis.

• Liquid biopsy development: ENO1 antibodies can detect circulating ENO1 in patient serum as a potential biomarker for tumor burden or treatment response.

• Companion diagnostics: As therapeutic ENO1 antibodies advance, diagnostic ENO1 antibodies can identify patients likely to respond to treatment based on ENO1 expression patterns or subcellular localization.

• Residual disease detection: High-sensitivity ENO1 antibodies may help detect minimal residual disease after treatment in cancers with ENO1 overexpression.

• Multiparameter analysis: Combining ENO1 antibodies with other cancer biomarkers in multiplexed assays can improve diagnostic accuracy and prognostic value.

These applications leverage ENO1's established role in cancer progression to develop clinically relevant tools for improving patient outcomes .